When a patient has remained free from seizures for several years while taking antiepileptic drugs (AEDI the question arises whether or not the medication can be withdrawn. Therefore it would be desirable to be able to identify reliably those patients who will remain seizure-free without treatment. Numerous variables might be of prognostic importance but our knowledge about the significance of demographic, genetic, aetiological, pathophysiological and treatment-related factors remains extremely poor. Although an abnormal inter-ictal EEG has been repeatedly cited as predictive of relapse during and after AED withdrawal, there is little evidence to support this view. There is a need for more precise individual prediction of risk but as long as patients with forms of epilepsy with widely varying prognosis are grouped together in AED withdrawal trials the outcome of these trials will never reach consensus about the relapse risk and about the possibility of predict relapse in individual patients. 
INTRODUCTION
There are marked disagreements in the figures published both for the probability of patients with epilepsy becoming seizure-free on medication and for avoiding relapse when it is withdrawn. The discrepancies are largely explained by different populations studied and different definitions used for epilepsy.
Becoming seizure-free on medication
In general, longitudinal or community-based surveys suggest a favourable prognoisis for remission, up to 70% of patients becoming seizure-free 1-6. In a longitudinal study of newly diagnosed adult epileptic patients, over 80% were seizure-free within 8 years 4'5. By contrast, cross-sectional studies in epileptological practice, based as they are on selected groups of patients with severe epilepsy, suggest a less favourable outcome, only 30-40% of adults becoming seizure-free, which means no seizures for at least two years 7's. A further difficulty is presented by patients with a history of a single seizure, one third of whom immediately receive antiepileptic drug {AED) therapy 9, so that it is impossible to determine what proportion would have suffered further seizures without medication. The apparent effect of age at onset of epilepsy will also depend upon the population studied. In institutionalized patients and those attending special centres for epilepsy, early seizure onset implies a poor prognosis for remission. In contrast, in less severely affected groups childhood onset is a favourable feature, particularly when febrile convulsions, absence attacks or benign childhood epilepsy are included. Indeed the longterm pattern of seizure control seems to be largely established during the first 2 years of treatment lo, 11
Remaining seizure-free during and after withdrawal of AEDs A similar disagreement is found in the literature concerning prognosis for remaining seizure-free when AEDs are withdrawn. Reported recurrence rates range from 6% to over 60% . With a worldwide prevalence between 1-2% the epilepsies are the second most common group of neurological disorders 6. The decision to withdraw antiepileptic drugs in seizure-free patients must take into account the natural history of the different epilepsies including the less-known history of the untreated epilepsies. Since the introduction of bromides in 1857 and the availability ofphenobarbitone and phenytoin in 1912 and 1939, respectively, the majority of patients have been treated.
Motivation to discontinue medication
When a patient, who has previously had epileptic seizures, has remained free from attacks for several years while taking anticonvulsant medication, the question arises whether the epilepsy has burnt itself out and therefore the medication can be withdrawn. The advantages are evident: a dose reduction means fewer sideeffects and less risk of teratogenesis; successful discontinuation eliminates the risk of idiosyncratic reactions, helps to remove the stigma of epilepsy an([ confers greater social freedom. Some patients may be unwilling to risk further epileptic seizures particularly if they have a driving licence and choose to continue medication, possibly at a reduced dose. Others find the drugs so troublesome that they would prefer to stop them, if at all possible.
Patients are particularly motivated to discontinue medication if suffering side-effects. Acute idiosyncratic and dose-related drug intoxications are rarely a problem for this eminently therapy-sensitive group, and chronic side effects such as gingival hypertrophy, hirsutism and fatigue will only in rare cases be an incentive for attempting withdrawal.
There are, however, increasingly welldocumented chronic toxic effects ~°-64. Late side-effects must be taken into account, particularly in young patients with a long life expectancy: in women of reproductive age because antiepileptic drugs have teratogenic effects s5-~2 and in males because of the possibility of reduced fertility 73. There is evidence that AEDs may have negative effects on the central nervous system such as behaviourial disorders (phenobarbitone) and pseudodementia (phenytoin), even in so called 'therapeutic' dosages 74-77. Drug interactions and liver enzyme induction may also give rise to problems 7s.
WITHDRAWAL OF ANTIEPILEPTIC DRUGS IN SUCCESSFULLY TREATED PATIENTS WITH EPILEPSY
The results of withdrawing antiepileptic medication in patients who have previously had epileptic seizures, but who have become seizurefree during treatment have been the subject of several studies ( Table 1 ). The rate of recurrence (i.e. seizures, including aura's within 2 years after AED withdrawal) varies widely between 6cA :~° and over 60~ 39 '43"4'5'47. The reason for these differences is to be found in the heterogeneity of the patient populations studied and perhaps also in the methods of withdrawing medication. It would be highly desirable to be able to identify reliably those patients who will remain seizurefree without treatment.
Therefore, the question arises whether there are any criteria that would reliably differentiate the patient who is likely to remain seizure-free from one who will relapse.
PREDICTION OF OUTCOME
Concerning prediction of outcome, again there is little agreement. Certain specific syndromes, notably benign epilepsy of childhood ls'31 and childhood absence epilepsy without associated tonic-clonic convulsions is' 19,31.32, clearly have a favourable prognosis. These two syndromes of childhood epilepsy, with a good prognosis both for control with medication and sustained remission when drugs are subsequently withdrawn, are probably responsible for the general observation that patients whose seizures begin early in life, and are promptly controlled, have the best prognosis of continued remission after AED withdrawal. Various clinical measures of severity of epilepsy (seizure type or types, total duration of epilepsy, maximum seizure frequency, seizure duration, etc.) are predictive of relapse in children and to some extent in adults. No other clinical features are of known predictive value in adults nor is there any consensus that the outcome is influenced by the period of remission prior to withdrawal, provided this is more than 2 years, nor the rate of withdrawal (in all reported studies this was more of less gradual). Published figures disagree about the probability of patients avoiding relapse on withdrawal. Although numerous variables ( Table 2 ) might be of prognostic importance, our knowledge about the significance of demographic-, genetic-, aetiological-, pathophysiological-and treatment-related risk factors remained extremely poor.
It is apparent that several of the primary variables considered in Table 2 show a significant association with outcome, but even reports from the same institution could not agree on which clinical variables are predictive, and no single variable could provide a basis for reliable prediction as'44.
The predictive value of the EEG fares a little better than the clinical features. To determine whether combinations of variable existed that would be of greater predictive reliability, multivariate analysis was performed in several studies 33'43'44"47"51'56. In a critical review Wallis (1987) has given explanations for the discrepancies found between different studies such as bias in the patient selection, difficulties in diagnostic classification resulting in grouping together of patients with forms of epilepsy with widely varying prognoses and a small number of patients in some of the trials 5°.
Most studies have provided some estimates of the average risk of seizure recurrence during and after AED withdrawal. However, average risks may not be relevant to an individual with epilepsy.
Epilepsy is not a single disease entity with one treatment and one prognosis. When speaking in general about this heterogeneous group of disorders with a wide variety of prognoses it should be better to use the term 'epilepsies' instead of the word 'epilepsy'. Therefore, there is a need for more precise individual prediction of risk. Only a few study-groups have developed a prognostic index 43'47"~s. The population studied by Overweg and colleagues was selected (patients from an epilepsy centre) and small and it is emphasized that the criteria used are applicable only to the particular type of patients studied. A few years after this first attempt, Chadwick and co-workers developed a prospective index, derived from the only randomized study. So far, this model provides the best available information for patients if drug withdrawal is being considered 5s. Both studygroups found the EEG to be of no predictive value to the risk of seizure recurrence. This most conflicting variable, the EEG, will be discussed below.
ELECTROENCEPHALOGRAPHY
The EEG is a valuable diagnostic tool, particularly during the initial evaluation of epilepsy, but it is the record of a short finite period 79's° and it would be difficult to justify on any scientific grounds a decision to prolong daily administrations of AED on the basis of the EEG alone, in the absence of other important fac-tors. Many neurologists take into account the EEG together with other clinical variables in deciding whether to withdraw or continue AED treatment. If drug withdrawal is undertaken, the EEG may be repeated on the reasonable, but unproved, assumption that a deteriorating record provides early warning of clinical relapse, which may be avoided by restoring medication. The only study with a series of EEG recordings prior to drug withdrawal (a standard registration of 30 minutes including a 5-minute period of hyperventilation and photic stimulation, a sleep tracing and a 6-hour telemetric recording), followed by EEGs when the dosage of each drug had been halved, again when reduced to zero, and 4 months after withdrawal of all drugs did not support the above-mentioned assumption 35'4"3'47. Neither the initial EEGs nor control registrations during withdrawal were predictive of relapse in this group of patients with partial seizures. However, the question whether AED should be discontinued if the EEG is abnormal remained controversial. Although an abnormal inter-ictal EEG has been repeatedly cited as predictive of relapse during or after AED withdrawal only a few studies offer any evidence to support this view 33'44'46'53. Indeed many investigators excluded from their studies patients whose initial EEGs were abnormal or abandoned AED withdrawals if the EEG deteriorated when medication was reduced. The studies in which EEG findings were predictive involved mainly children with idiopathic generalized epilepsy. Despite all (mostly a-priori) meanings about the predictive value of the EEG prior to and during drug withdrawal, the preponderance of evidence indicates that an abnormal EEG (spiky and not-spiky abnormalities) is not associated with an increased risk of seizure-recurrence in adults and in children with a localization-related epilepsy. In children and adults with an idiopathic generalized epilepsy (e.g. absence-attacks and seizures belonging to the juvenile myoclonus epilepsy) and in photo-sensitive patients the EEGs are positively associated with the outcome of drug withdrawal sl-8~.
Apart from the limitations of the EEGregistrations, the interpretation of the EEG may vary from observer to observer s4. This variability is influenced by specific reader characteristics. Various investigators employ different definitions of epileptiform activity and use different recording techniques both leading to different interpretations of the EEGs.
REMARKS ABOUT THE PREDICTIVE VALUE OF THE EEG Definitions
From Gastaut's definition of paroxysmal epileptiform activity 'A wave or group of waves constituting the EEG presentation of an epileptic discharge which appears and disappears randomly and is characterized by a frequency, morphology or amplitude that clearly differentiates it from the background activity of the EEG' the impression could be gained that every paroxysmal discharge is epileptiform, which is not true.
For the purpose of antiepileptic drug withdrawal studies the definition of epileptiform activity conforms with that in Gastaut's dictionary of epilepsy s2 and in addition with the opinion of Zivin and Ajmone Marsan s°, in practice the discharges classified as epileptiform are limited to spikes and sharp waves with and without slow components.
Zivin and Ajmone Marsan used the topographical distribution as a criterion in addition to the paroxysmal character of the events s°. They separated three main groups of epileptiform discharges, namely: (1) bilateral diffuse {gen-eralized), (2) bilateral non-diffuse (i.e. limited to one or two regions, synchronous or independent}, and (3) focal or partial.
Limitations of the EEG-recording
A frequently underestimated limitation of extracranial EEG recordings derives from the fact that the voltage of electrical potentials generated by the brain drops inversely proportionally to the square of the distance s6.
Inter-ictal and ictal scalp recordings often provide limited information on the side and dimension of a discharging lesion for three major reasons 87.
1. Only 1/6-1/5 of the total cerebral cortex is accessible to the conventional EEG. The depth of fissures or sulci and mesial as well as inferior surfaces of the hemispheres are not directly accessible. 2. A scalp-derived signal can be projected from a distant source and is therefore sometimes a misleading localizing sign. 3. The biophysical requirements for appearance of spikes or sharp waves in ictal discharges are not always fulfilled at the scalp s~.
Pathophysiology
The importance of the EEG to present concepts of epilepsy and for the classifications of the epilepsies and the epileptic seizures would be difficult to exaggerate. There is nevertheless little justification for the extrapolation underlying the belief that inter-ictal epileptiform discharges are meaningful measures of severity. A lack of association between the outcome of drug withdrawal and epileptiform EEG activity may appear surprising, but only if one accepts the widespread and unsubstantiated assumption that the presence and amount of inter-ictal epileptiform activity is closely related to seizure frequency, severity and prognosis of epilepsy. However, one should reconsider the assumption that the interictal discharge rate should be expected to reflect seizure frequency. Inter-ictal discharges are often dramatic, of high voltage, generalized and prolonged. By contrast, particularly in the partial epilepsies, the EEG changes seen at seizure onset often consist of electrodecremental events of inconspicuous runs of rhythmic activity without a spiky waveform, this serving to emphasize the dissociation between epileptiform inter-ictal EEG discharges and clinical seizures. Epileptogenesis involves a succession of events in which at least three distinct levels of organization can be recognized {Table 3). The epileptogenic neuron or neuronal population exhibits almost continuous electrophysiological abnormality. In the context of such a model {Table 3) the relationship between seizure frequency and the inter-ictal EEG will largely depend upon seizure propensity.
Inter-ictal discharges registered with surface and with intra-cranial recordings
In all AED-withdrawal studies the predictive value of the EEG is based upon surface EEG recordings. EEG registrations with depth electrodes as used in the pre-operative screening for epilepsy surgery have shown that patterns recordable in deep cortical structures usually cannot be picked up on the scalp s6's7"91-93.
In Figs 1 and 2 the discrepancy that can exist between depth and surface EEG recordings is illustrated. Figure 1 shows continuous discharges in the deep structures, at the same time the scalp EEG (Fig. 2) is normal with one exception, a sharp wave that easily could be missed or not recognized as a specific epileptiform activity.
Transition to the third level of epileptogenesis, clinical expression as an ictal event, appears also to involve the crossing of a threshold (see also pathophysiology). Possibly there are patients with effective inhibitory mechanisms showing numerous inter-ictal discharges which rarely find clinical expression. By contrast, lack of such inhibition may result in a larger proportion of discharges producing clinical effects so that relatively few discharges are inter-ictal.
Obviously the first two stages of epileptogenesis are necessary for the third to occur but this second threshold may account for the fre-quent lack of positive correlation between seizure frequency and inter-ictal discharge rate.
False positive and false negative EEG findings
False positive and false negative findings are matter over which there are a number of misunderstandings. Spikes, sharp waves and particularly spike or sharp and slow wave complexes are commonly registered during seizures and in the inter-ictal record of patients with epilepsy. They may however also occur in the EEGs of people who do not apparently have epileptic seizures s°. Conversely a seizure may be accompanied by an EEG change which is related to the fit but does not have the characteristic wave form. One may for instance see a run of focal theta activity of appropriate distribution during partial seizures and think this activity is not 'epileptiform' in the sense of being spiky, however, it is clearly 'epileptic' in the sense that it is a reflection of the fit.
The same phenomena are seen in inter-ictal surface recordings, often bursts of irregular slow wave activity without sharp waves, activity that is not specific 'epileptiform' in the sense of being spiky. In Figs 3 and 4 , a surface and a depth recording in the same patient and at the same time are shown. The 'not specific epileptiform activity' picked up with the surface electrodes actually reflects true epileptiform activity in the depth.
Association between epileptiform discharges and overt seizures
There are well-known epilepsy syndromes with a closed association between the amount of discharges and clinical or sub-clinical epileptic seizures, as juvenile myoclonic epilepsy s2, photosensitive epilepsy s3 and childhood absence epilepsy sl. Even if patients with these syndromes are seizure-free for 2, 3 or even more years, but the EEGs consist epileptiform discharges, drug withdrawal will not succeed because of seizure recurrence. It is remarkable that this firm association exists in the abovementioned generalized seizure disorders. On the other hand, most of the partial seizure disorders do not have such a clear association between clinical and EEG features.
Although functional abnormalities, both electrophysiological and biochemical, are continually present in the epileptic brain tissue, it is only at intervals ranging from tens of milliseconds to hours or even days that synchronous discharges become sufficiently widespread to be detectable with EEG electrodes. Only a fraction (and sometimes none} of these discharges are associated with overt clinical seizures. The mechanism underlying discharges detectable in the EEG are poorly understood, and less is known about the factors determining whether or not they produce clinical manifestations. While it is reasonable to expect that correction of the underlying neuronal dysfunction by medication or by spontaneous remission should necessarily abolish both EEG discharges and seizures, it seems naive to suppose that this is the only mechanism by which a patient can become seizure-free. Any change in the liability of neuronal discharge giving rise to clinical manifestations (described by Rodin as 'seizure propensity'} would result in a dissociation between EEG findings and clinical state v. Most findings so far suggest that in many patients remission of epilepsy does not reflect a reduction in neuronal functional abnormality but rather a diminution in seizure propensity.
The practice of continuing antiepileptic drug medication in patients who have long been seizure free simply on account of an abnormal EEG, or resuming medication if epileptiform activity increases during antiepileptic drug withdrawal, is clearly not justified.
Long-term EEG/video-monitoring
In the course of previous studies of long-term monitoring 47'94'9'~ it had emerged that some patients exhibited numerous brief seizures which were not readily recognized either by the patient or by those about them without help of simultaneous EEG registration. To reduce the risk of such patients, who are wrongly supposed to be seizure-free, being included in a AED withdrawal procedure, longterm monitoring could be carried out prior to AED withdrawal. The importance of this measure is highlighted by the fact that in a group of 72 seizure-free patients, nine (11%) were demonstrated, even within a brief period of some 5 to 6 hours of monitoring, not to be seizure-free 4v. Eight of them exhibited EEG discharges accompanied by short periods of impairment of consciousness, with or without myoclonic movements, of which both they themselves and their relatives had been unaware. In the whole group five patients were of low normal intelligence, which may explain why they themselves were unaware of the short periods of impairment of consciousness. The value of the long-term EEG monitoring in clinical practice which has been emphasized over one decade ago by several authors is once more confirmed 94-97. Video monitoring of behaviour during long-term EEG telemetry 94 and continuous assessment of cognitive functions by performance tests 9'~'9s indicate that runs of generalized spike wave complexes are usually accompanied by either behavioural-or cognitive changes and may thus virtually be equated with seizure themselves 9s. Another point of interest is the finding that four of these nine patients were photosensitive whilst three exhibited self-induction by slow eyeclosure 99-t°1. So, when the question of withdrawing antiepileptic drugs arises, it is advisable to do long-term EEG monitoring. In cases of generalized epileptiform discharges, even when impairment of consciousness is not clinically apparent, it is worthwhile performing tests to demonstrate any transient cognitive impairment 95,98.
GUIDELINES FOR ANTIEPILEPTIC DRUG WITHDRAWAL
General procedure prior to and during drug withdrawal On admission to withdraw the antiepileptic medication each patient's case history should be reviewed and augmented as necessary and a full neurological examination has to be performed. A full diagnostic EEG examination has to be carried out to ascertain the classification of the seizure type(s) and the classification of the epilepsy. In addition long-term telemetric EEG registrations of some hours duration has to be considered. Blood levels of all antiepileptic drugs used by the patient must be checked and drug withdrawal commenced following a standardized procedure. The patients have to be followed up clinically for at least 2 years after stopping all medication. In the event of recurrence of seizures the patient has to be immediately withdrawn from further drug discontinuation and further management has to be adapted to the individual circumstances. In most instances this involved at least partial restoration of the previous medication, but in most cases it has to be considered appropriate to continue treatment PB  300  250  200  150  100  75  50  25  PRM  1750  1500  1250  1000  750  500  250  125  PHT  400  350  300  250  200  150  100  50  ESM  1500  1250  1000  750  500  250  CBZ  1600  1400  1200  1000  800  600  400  200  VPA  2400  2100  1800  1500  1200  900  600  300 Abbreviations: PB, phenobarbitone; PRM, primidone; PHT, phenytoin; ESM, ethosuximode; CBZ, carbamazepine; VPA, valproate.
at a reduced level, or even at a later date, to continue AED withdrawal. Each patient has to be instructed in the event of relapse immediately to resume the previous medication and to contact the general practitioner or medical specialist. Further management thereafter is individualized. All patients could be also supplied with two rectioles of 10 mg diazepam to be used in the event of a series of seizures or a threatening status epileptics.
Drug withdrawal procedure
The drugs can be divided into groups of first (the major AEDs as carbamazepine, phenytoin and valporate), second (ethosuximide, phenobarbitone) and third choice (primidone or a benzodiazepine). Not yet mentioned are relatively new compounds like oxcarbazepine, lamotrigine, vigabitrine, felbamate and other new AEDs, drugs to be expected first choice AEDs. This classification is based both on general epileptological practice and in particular the relative efficacy and side effects. Presumably the drugs of third choice are of some benefit to certain patients, otherwise their registration as antiepileptic drug would be unjustified. In patients taking multiple drugs, any drug of third choice has to be withdrawn first, then those of second choice and finally of first choice. Where a patient is receiving two drugs of first choice, then the order of withdrawal has to be determined by their probable efficacy in the type of epilepsy in question. The period of time over which the various drugs will be withdrawn could follow the schedule set out in Table 4 taking into account the characteristics of the various different antiepileptic drugs.
Duration of withdrawal
The rate of withdrawal is related to the initial medication in such a way that a large dose is withdrawn over a longer period of time, passing from eventual polypharmacy to monotherapy, ending in a single daily dose in the final phase. According to Todt the length of the reduction period is an important factor and the relapse risk decreases when withdrawal is undertaken over at least 6 months 34A1. According to the results of Juul-Jensen and Tennison, by contrast the length of the period of discontinuation does not exert any influence on the frequency of recurrence 16' lo2. Figure 5 shows the time relation between drug withdrawal and seizure recurrence in the study of Van Heycop ten Ham and in the study of Overweg 31'43. Most recurrences are seen in close relation to the attempted discontinuation of medication. Some two-thirds of the patients who relapsed did so during withdrawal and 80~ within 3 months after stopping all medication. In the following 10 years there was a progressive decline in the frequency of the recurrences. There was no difference in the risk of relapse between a 4 months (Overweg) and a 30 months (Van Heycop ten Ham) period of drug discontinuation. It is reasonable to expect that, if an anticonvulsant level becomes inadequate, regardless over what period of time, and the patient still has a seizure disorder, he will sooner or later have an attack. An exception is provided by the effects of rapid AED withdrawal per se, which can provoke generalized convulsions, particularly in the case of barbiturates and benzodiazepines. It can be concluded that the duration of AEDwithdrawal depends on the number of drugs taken and their pharmacokinetic properties. Withdrawal time (weeks or months) does not influence the outcome 16'43A°2.
DISCUSSION
In general, the findings in the literature on AED withdrawal confirm that no single variable is reliably predictive of outcome. The proposition that epileptiform EEG activity should be predictive of relapse has been regarded by most previous investigators to be so self-evident that it would be ethically unacceptable to put it to the test. Only a few prospective studies including adults 43'47'5°''~6 have addressed this issue all with negative conclusions. Despite widely held opinions to the contrary, these findings are hardly surprising as, except in children and particularly in absence seizures, and in photosensitive epilepsy both in children and adults, there is little evidence that the EEG provides a useful measure of seizure liability or of antiepileptic drug effects ms-l°5. Although functional abnormalities, both electrophysiological and biochemical, are continually present in epileptic brain tissue, it is only at intervals ranging from tens of milliseconds to hours or even days that synchronous discharges become sufficiently widespread to be detectable with EEG electrodes~06.107.
Only a fraction (sometimes none) of these discharges is associated with overt clinical seizures. The mechanisms underlying discharges detectable in the EEG are poorly understood, and less is known of the factors determining whether or not they produce clinical manifestations. While it is reasonable to expect that correction of the underlying neuronal dysfunction by medication or by spontaneous remission should necessarily abolish both EEG discharges and seizures, it seems naive to suppose that this is the only mechanism by which a patient can become seizure-free. Any change in the liability of neuronal discharge to give rise to clinical manifestations, described as seizure propensity 7, would result in dissociation between EEG findings and clinical state. In many patients remission of epilepsy does not reflect a reduction in neuronal functional abnormality but rather a diminution in seizure propensity. In fact there is a weak association between the more florid types of epileptiform discharge and relapse and this might have attained statistical significance in a larger sample. Studying EEG and other early predictors of epilepsy remission EEG findings other than generalized epileptiform activity were not significantly related to either endpoint l°s.
The question arises if these patients with generalized epileptiform discharges have to be considered seizure-free as has been pointed out previously in this paper.
Prognostic index for seizure recurrence in seizure-free patients Currently the best available aid for counselling patients who suffered from epileptic seiz-ures and who have been seizure-free for at least 2 years is the model developed by Chadwick and co-workers 5s. This prognostic model (Table 5) represents an important application of data from the only randomized study of AED-withdrawal from patients in remission. As such this model provides the best available information when discontinuation of medication is considered. 
SUMMARY
A question of practical clinical importance is whether AEDs can be withdrawn after the patient has been seizure-free for a given period of time. Opinions vary concerning the relationship between the relapse rate and seizure types. For absence attacks the risk of relapse is low, as is the risk of relapse in partial seizure in the benign epilepsy of childhood with Rolandic spikes. There is a trend toward an increase in the relapse rate in patients with partial seizures, particularly complex partial seizures. Almost all authors agree that the relapse risk is greatest in patients with partial seizures with secondary generalization (to tonic-clonic seizures) and in juvenile myoclonus epilepsy. The total number of seizures and the duration of the seizure disorder prior to remission seems to be related to the likelihood of relapse. The literature is fairly unanimous that the time between the first and the last seizure (i.e. duration of the illness) as well as severe mental subnormality are related to the risk of relapse. The length of the seizure-free period is a determinant for good outcome. There is a trend discernible toward a higher risk of relapse when blood levels of antiepileptic drugs were high. The total number of AEDs used prior to drug discontinuation is a factor that influences the outcome. Although, in general, the value of the EEG is doubtful in predicting seizure recurrence during and after antiepileptic drug discontinuation, there are at least three prospective studies (all in children) which indicate a higher relapse risk when the EEG prior to discontinuation of medication shows epileptiform (including paroxysmal slow wave) activity. It is advisable to perform longterm EEG/video monitoring prior to drug discontinuation. In cases of generalized epileptiform discharges, even when impairment of consciousness is not clinically apparent, it is worthwhile attempting to demonstrate transient cognitive impairment.
SUGGESTIONS FOR FUTURE RESEARCH
Only randomized and multicentre prospective studies of relapse during and after drug withdrawal versus continuing drug treatment would help to determine predictors of seizure recurrence. The first step in future studies is to avoid heterogeneity in seizure-and epilepsy types to be studied. As long as patients with forms of epilepsy with a widely varying prognosis will be grouped together in AED-withdrawal trials, the outcome of these trials will never reach consensus concerning the relapse rate and concerning the possibility to predict relapse in individual patients.
